McKesson Corporation vs Wheaton Precious Metals Corp — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Wheaton Precious Metals Corp trades at $138 (market cap $61.17B). The key difference: McKesson Corporation is the larger of the two by market cap, and Wheaton Precious Metals Corp pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Wheaton Precious Metals Corp for 66 Days on average.
| MCK | WPM | |
|---|---|---|
Market Cap | $108.46B | $61.17B |
Volume | 712,607 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $165.72 |
52-Week Low | $725.17 | $94.37 |
Typical Hold Time | 74 Days | 66 Days |
Enterprise Value | $115.00B | $63.05B |
Dividend Yield | 0.4% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% today, amid a bearish technical signal. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, driven by high margins and consistent earnings beats. Recent news highlights expansion plans targeting 1.2M ounces by 2030, supported by a robust deal pipeline. Analyst consensus remains strongly bullish with an 80% buy rating and a $164.80 price target, suggesting significant upside from current levels despite near-term technical weakness.
The outlook for WPM is positive due to strong earnings growth, high profitability, and strategic streaming acquisitions. Risks include exposure to gold/silver price volatility, execution of growth targets, and macroeconomic factors like interest rates. With solid cash flow and institutional support, the stock presents a compelling long-term opportunity, though investors should monitor commodity cycles and operational milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →